BOT - Anything but charting, page-7135

Here's where I am at, and this is not financial advice, you should always do your own research.
The share price will kick around this level for a while, but there are some key points where the SP should increase:
1. When the FDA starts the clock on their assessment of the NDA resubmission. Whether this becomes a 2-month or 6-month process is less relevant. That said, if the FDA chooses a 2-month turnaround, watch for faster movements in the SP.
2. When the latest sales figures from Japan come in. I would expect this next report to be good, but the one after will be (most likely) down due to winter and the natural disasters.
3. When the FDA announces that Sofdra is approved.
4. When Sofdra hits the US market. BOT has indicated that their entire focus is now on commercialisation so that they can hit the ground running.
5. When the first US sales figures are released. And this is a big one and likely to give the SP a real kick along. We might even get a speeding infringement notice from the ASX - here's hoping.

Of course, all this fall away if Big Pharma cast serious eyes in BOT's direction. Sofdra and the pipeline are very attractive. So if 2 or more BPs have a tilt, sit back and enjoy the ride.
is BOT still worth getting into? In my opinion, absolutely! Me? I have reached my limit and I am happy with that.
GLTA